These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 40725)

  • 1. Kinetics of pamatolol, a cardioselective beta adrenoreceptor blocker.
    Carruthers SG; Pentikainen P; Hosler JP; Azarnoff DL
    Clin Pharmacol Ther; 1979 Dec; 26(6):682-5. PubMed ID: 40725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker.
    Brown HC; Carruthers SG; Johnston GD; Kelly JG; McAinsh J; McDevitt DG; Shanks RG
    Clin Pharmacol Ther; 1976 Nov; 20(5):524-34. PubMed ID: 10125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pamatolol: phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug.
    Carruthers SG; Hosler JP; Pentikainen P; Azarnoff DL
    Clin Pharmacol Ther; 1978 Aug; 24(2):168-74. PubMed ID: 28193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The pharmacokinetics of 1-(4-cyclohexylureidophenoxy)-2-hydroxy-3-tert-butylaminopropane (talinolol, Cordanum, 02-115). 1. Blood levels in dogs].
    Femmer K; Klemm W; Nürnberger H
    Pharmazie; 1975 Oct; 30(10):673-5. PubMed ID: 694
    [No Abstract]   [Full Text] [Related]  

  • 5. Relationship between plasma concentrations and cardiac beta-adrenoceptor blockade--a study with oral and intravenous bopindolol.
    Aellig WH; Nüesch E; Engel G; Grevel J; Niederberger W; Rosenthaler J
    Br J Clin Pharmacol; 1986 Jan; 21(1):45-51. PubMed ID: 2868747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood concentrations and pharmacodynamic effects of betaxolol (SL 75212) a new beta-adrenoceptor antagonist after oral and intravenous administration.
    Warrington SJ; Turner P; Kilborn JR; Bianchetti G; Morselli PL
    Br J Clin Pharmacol; 1980 Nov; 10(5):449-52. PubMed ID: 6108127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of adimolol after single and multiple dose administration in healthy volunteers.
    Wiedemann I; Peil H; Justus H; Adamus S; Brantl V; Lohmann H
    Arzneimittelforschung; 1985; 35(6):964-9. PubMed ID: 2862877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
    Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
    Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of a single intravenous and oral dose of pafenolol--a beta 1-adrenoceptor antagonist with atypical absorption and disposition properties--in man.
    Regårdh CG; Lundborg P; Gabrielsson M; Heggelund A; Kylberg-Hanssen K
    Pharm Res; 1990 Dec; 7(12):1222-7. PubMed ID: 1982773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absolute bioavailability study in the dog with Visacor, a new cardioselective beta blocking drug with intrinsic sympathomimetic activity.
    McAinsh J; Smith RP; Ferguson RA
    Eur J Drug Metab Pharmacokinet; 1984; 9(2):129-39. PubMed ID: 6146530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood concentrations and pharmacodynamic effects of SL 75212, a new beta-adrenoceptor antagonist, after oral and intravenous administration [proceedings].
    Bianchetti G; Gomeni R; Kilborn JR; Morselli PL; Taylor EA; Warrington SJ
    Br J Clin Pharmacol; 1979 Oct; 8(4):403P-404P. PubMed ID: 41556
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.
    Gillies HC; Rogers HJ; Francis RJ; Galloway DB; Humphreys JE
    Eur J Clin Pharmacol; 1986; 31(1):113-5. PubMed ID: 2877883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs.
    Arsenault WG; Boothe DM; Gordon SG; Miller MW; Chalkley JR; Petrikovics I
    Am J Vet Res; 2005 Dec; 66(12):2172-6. PubMed ID: 16379664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute bioavailability and dose proportionality of betaxolol in normal healthy subjects.
    Ludden TM; Boyle DA; Gieseker D; Kennedy GT; Crawford MH; Ludden LK; Clementi WA
    J Pharm Sci; 1988 Sep; 77(9):779-83. PubMed ID: 2906367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of betaxolol in middle aged patients.
    Bianchetti G; Thiercelin JF; Thenot JP
    Eur J Clin Pharmacol; 1986; 31(2):231-3. PubMed ID: 2879735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug.
    Balnave K; Neill JD; Russell CJ; Harron DW; Leahey WJ; Wilson R; Shanks RG
    Br J Clin Pharmacol; 1981 Feb; 11(2):171-80. PubMed ID: 6111331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Species differences in the metabolism of pamatolol, a cardioselective beta--adrenoceptor antagonist.
    Hoffmann KJ; Skånberg I; Borg KO
    Eur J Drug Metab Pharmacokinet; 1979; 4(3):163-73. PubMed ID: 43252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic characteristics of bornaprolol in healthy volunteers.
    Cheymol G; Cheymol A; Jozefczak C; Lecoq V; Lecoq B; Jaillon P
    Xenobiotica; 1990 Aug; 20(8):855-60. PubMed ID: 1977241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.